Finastéride oral 1 mg face à Serenoa repens 320 mg par voie orale
1 essai les comparent directement, sur les mêmes patients. Voir Finastéride oral 1 mg · Voir Serenoa repens 320 mg par voie orale
Un seul essai de fiabilité limitée, chez 100 hommes de 20 à 40 ans atteints d'alopécie androgénétique légère à modérée, a opposé le finastéride oral 1 mg au Serenoa repens 320 mg (Rossi 2012). Après deux ans, le finastéride fait mieux sur photos jugées à l'aveugle : 68 % d'hommes améliorés contre 38 %. Le Serenoa repens laisse davantage d'hommes simplement stabilisés (52 % contre 22 %, sans que l'écart soit testé), et 10 % des hommes s'aggravent dans chaque groupe. Aucun effet indésirable ni arrêt de traitement n'est rapporté, d'un côté comme de l'autre (0 sur 50).
Rossi 2012
Essai randomisé, risque de biais élevé. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study
| Critère | Finastéride oral 1 mg | Serenoa repens 320 mg par voie orale | Écart |
|---|---|---|---|
| Patients améliorés (panel photo en aveugle) | 68 %Voir la citationFrom Table II it can be observed that 68% of patients treated with finasteride had a score greater than 0, while these were 38% when Serenoa repens was used; therefore this treatment led to an improvement of clinical condition, but finasteride resulted moreeffective. Citation complémentaire (significativite) The result of the Mann-Whitney's test U when it considered the final score for the two samples TableI.Distribution ofpatients according to the treatment (874.5, with a value ofz, in the two tails case, of 2.84), shows that these were not comparable (it is possible to refuse the null hypothesis because the associatedp-value was less than 0.05). However, it Rossi A, Mari E, Scarno M et al.. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. International Journal of Immunopathology and Pharmacology 2012, DOI 10.1177/039463201202500435. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | 38 %Voir la citationFrom Table II it can be observed that 68% of patients treated with finasteride had a score greater than 0, while these were 38% when Serenoa repens was used; therefore this treatment led to an improvement of clinical condition, but finasteride resulted moreeffective. Citation complémentaire (significativite) The result of the Mann-Whitney's test U when it considered the final score for the two samples TableI.Distribution ofpatients according to the treatment (874.5, with a value ofz, in the two tails case, of 2.84), shows that these were not comparable (it is possible to refuse the null hypothesis because the associatedp-value was less than 0.05). However, it Rossi A, Mari E, Scarno M et al.. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. International Journal of Immunopathology and Pharmacology 2012, DOI 10.1177/039463201202500435. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | Probablement réel |
| Patients dont l'état s'est aggravé | 10 %Voir la citationis interesting to observe that neither treatment was effectivein 10%ofpatients andthatSerenoa repens stabilizetheAGAin52%ofthe cases. Rossi A, Mari E, Scarno M et al.. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. International Journal of Immunopathology and Pharmacology 2012, DOI 10.1177/039463201202500435. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | 10 %Voir la citationis interesting to observe that neither treatment was effectivein 10%ofpatients andthatSerenoa repens stabilizetheAGAin52%ofthe cases. Rossi A, Mari E, Scarno M et al.. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. International Journal of Immunopathology and Pharmacology 2012, DOI 10.1177/039463201202500435. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | Non testé |
| Patients stabilisés, sans gain ni perte | 22 %Voir la citationTreatment Finasteride Serenoa Repens lmg/die 320mg/die 5 (10%) 5 (10%) 11(22%) 26 (52%) 30 (60%) 19 (38%) 3 (6%) 0(0%) 1(2%) 0(0%) 50 (100%) 50 (100%) Citation complémentaire (methode) TableII. Distributionofpatientsfortreatment (Finasteride scores at theendofthetreatment (T24). Score at the end ofthe treatment (T24) -1 0 1 2 3 Totale Columnpercentagesareinparenthesis. Rossi A, Mari E, Scarno M et al.. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. International Journal of Immunopathology and Pharmacology 2012, DOI 10.1177/039463201202500435. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | 52 %Voir la citationis interesting to observe that neither treatment was effectivein 10%ofpatients andthatSerenoa repens stabilizetheAGAin52%ofthe cases. Rossi A, Mari E, Scarno M et al.. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. International Journal of Immunopathology and Pharmacology 2012, DOI 10.1177/039463201202500435. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | Non testé |
| Arrêt pour effet indésirable | 0 % (0 sur 50)Voir la citationofthe AGA (21 of35, i.e. 60%). In both groups all the patientsremainedinthe study and no side effects were observed. Rossi A, Mari E, Scarno M et al.. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. International Journal of Immunopathology and Pharmacology 2012, DOI 10.1177/039463201202500435. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | 0 % (0 sur 50)Voir la citationofthe AGA (21 of35, i.e. 60%). In both groups all the patientsremainedinthe study and no side effects were observed. Rossi A, Mari E, Scarno M et al.. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. International Journal of Immunopathology and Pharmacology 2012, DOI 10.1177/039463201202500435. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | Non testé |
| Incidence d'un effet indésirable, toutes natures confondues | 0 % (0 sur 50)Voir la citationofthe AGA (21 of35, i.e. 60%). In both groups all the patientsremainedinthe study and no side effects were observed. Rossi A, Mari E, Scarno M et al.. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. International Journal of Immunopathology and Pharmacology 2012, DOI 10.1177/039463201202500435. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | 0 % (0 sur 50)Voir la citationofthe AGA (21 of35, i.e. 60%). In both groups all the patientsremainedinthe study and no side effects were observed. Rossi A, Mari E, Scarno M et al.. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. International Journal of Immunopathology and Pharmacology 2012, DOI 10.1177/039463201202500435. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | Non testé |